<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00059904</url>
  </required_header>
  <id_info>
    <org_study_id>CHIR-IL2005-A01</org_study_id>
    <secondary_id>MSKCC-03004</secondary_id>
    <secondary_id>CDR0000298986</secondary_id>
    <nct_id>NCT00059904</nct_id>
  </id_info>
  <brief_title>Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma</brief_title>
  <official_title>An Open-Labeled, Phase II Study of Rituximab in Combination With Recombinant IL-2 for Relapsed or Refractory Non-Hodgkin's Lymphoma of Intermediate- or High-Grade Histology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill&#xD;
      them or deliver cancer-killing substances to them without harming normal cells. Interleukin-2&#xD;
      may stimulate a person's white blood cells to kill cancer cells. Combining rituximab with&#xD;
      interleukin-2 may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining rituximab with interleukin-2&#xD;
      in treating patients who have relapsed or refractory intermediate- or high-grade&#xD;
      non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the clinical efficacy of rituximab and interleukin-2 in patients with relapsed&#xD;
           or refractory intermediate- or high-grade non-Hodgkin's lymphoma.&#xD;
&#xD;
        -  Determine the 2-year progression-free survival of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the safety of this regimen in these patients.&#xD;
&#xD;
        -  Correlate response with natural killer cell numbers and rituximab, interleukin-2 (IL-2),&#xD;
           and soluble IL-2 receptor levels in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study.&#xD;
&#xD;
      Patients receive rituximab IV once weekly on weeks 1-4 and interleukin-2 subcutaneously 3&#xD;
      times weekly on weeks 2-9. Treatment continues in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 12 weeks for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 50-100 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of intermediate- or high-grade non-Hodgkin's lymphoma according to the&#xD;
             Working Formulation, including the following subtypes:&#xD;
&#xD;
               -  Diffuse large cell lymphoma&#xD;
&#xD;
               -  Diffuse mixed cell lymphoma&#xD;
&#xD;
               -  Immunoblastic large cell lymphoma&#xD;
&#xD;
          -  CD20+ disease&#xD;
&#xD;
          -  Measurable progressive or refractory disease&#xD;
&#xD;
          -  No primary CNS lymphoma or lymphomatous meningitis NOTE: A new classification scheme&#xD;
             for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of&#xD;
             &quot;indolent&quot; or &quot;aggressive&quot; lymphoma will replace the former terminology of &quot;low&quot;,&#xD;
             &quot;intermediate&quot;, or &quot;high&quot; grade lymphoma. However, this protocol uses the former&#xD;
             terminology.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Lymphocyte count less than 20,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 75,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9.5 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  SGOT and SGPT no greater than 1.5 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  No liver disease&#xD;
&#xD;
          -  Hepatitis C-seropositive patients are allowed provided they have no active disease, as&#xD;
             demonstrated by any of the following:&#xD;
&#xD;
               -  Undetectable hepatitis C viral loads&#xD;
&#xD;
               -  Biopsy showing no active disease&#xD;
&#xD;
               -  Normal transaminases on at least 3 different occasions within the past year&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No clinically significant cardiac dysfunction&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No heart failure within the past 6 months&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No clinically significant pulmonary dysfunction&#xD;
&#xD;
          -  Patients with prior radiotherapy to the lung or autologous transplantation must have&#xD;
             FEV greater than 50% and DLCO greater than 50% within 8 weeks before study treatment&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No significant infections within the past 2 weeks (including pneumonia or bronchitis)&#xD;
&#xD;
          -  No history of autoimmune disease&#xD;
&#xD;
          -  No prior or concurrent malignancy except inactive nonmelanoma skin cancer, carcinoma&#xD;
             in situ of the cervix, or other solid tumor curatively treated with no evidence of&#xD;
             recurrence within the past 2 years&#xD;
&#xD;
          -  No symptomatic thyroid disease requiring medical intervention other than replacement&#xD;
             treatment for hypothyroidism&#xD;
&#xD;
          -  No prior type 1 hypersensitivity or anaphylactic reactions to murine products,&#xD;
             rituximab, or radioimmunoconjugated anti-CD20 antibody infusion&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 3 months since prior autologous bone marrow transplantation&#xD;
&#xD;
          -  No prior allogeneic bone marrow transplantation&#xD;
&#xD;
          -  No prior interleukin-2&#xD;
&#xD;
          -  No prior interferon (alfa, beta, or gamma)&#xD;
&#xD;
          -  No concurrent basiliximab, daclizumab, or monoclonal antibody OKT3&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 30 days since prior chemotherapy&#xD;
&#xD;
          -  No concurrent anticancer chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 2 weeks since prior systemic steroids&#xD;
&#xD;
          -  No concurrent systemic corticosteroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 30 days since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 30 days since prior major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 30 days since other prior investigational drugs&#xD;
&#xD;
          -  More than 30 days since prior immunosuppressive medications&#xD;
&#xD;
          -  No concurrent immunosuppressive medications including the following:&#xD;
&#xD;
               -  Cyclosporine&#xD;
&#xD;
               -  Mycophenolate mofetil&#xD;
&#xD;
               -  Tacrolimus&#xD;
&#xD;
               -  Sirolimus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tarun Kewalramani, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2004</verification_date>
  <study_first_submitted>May 6, 2003</study_first_submitted>
  <study_first_submitted_qc>May 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2003</study_first_posted>
  <last_update_submitted>July 17, 2013</last_update_submitted>
  <last_update_submitted_qc>July 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2013</last_update_posted>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

